ABSTRACT

Introduction: Point-of-care (POC) tests for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are urgently needed to control the STI epidemic in order to offer patients an immediate diagnoses and accurate treatment before they leave a clinical encounter and thus reduce transmission and sequelae. Nucleic acid amplification tests (NAATs) have increased sensitivity and specificity, but very few POC assays can provide results of such tests within the usual time of the patient visit.

Areas covered: This review describes the technology and performance characteristics of the binx health io® [Boston, MA] (binx io) CT/NG assay, a new rapid molecular POC assay. The assay is compared to other available molecular POC tests. We also describe the importance of time to results and assay performance for this POC assay.

Expert opinion: The binx io CT/NG assay offers the ability to incorporate the use of POC tests to identify and immediately treat chlamydia and gonococcal infections into the clinical visit, which will provide improved outcomes for patients. Additional implementation studies are needed to optimize the adoption of this new test.

摘要

简介: 迫切需要对沙眼衣原体(CT)和淋病奈瑟菌(NG)进行床旁检测 (POC) 检测，以控制 STI 流行，以便在患者离开临床之前为他们提供即时诊断和准确治疗，从而减少传播和后遗症。核酸扩增测试 (NAAT) 具有更高的灵敏度和特异性，但很少有 POC 测定可以在患者就诊的正常时间内提供此类测试的结果。

涵盖的领域：本综述描述了 binx health io ® [马萨诸塞州波士顿] (binx io) CT/NG 检测的技术和性能特征，这是一种新的快速分子 POC 检测。将该测定与其他可用的分子 POC 测试进行比较。我们还描述了这种 POC 测定的结果时间和测定性能的重要性。

专家意见：binx io CT/NG 检测能够将 POC 测试的使用结合起来，以识别并立即治疗衣原体和淋球菌感染，从而为患者提供更好的结果。需要额外的实施研究来优化这项新测试的采用。